Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

UCAM (participant 2) is responsible for CIMBA. CIMBA is an international consortium evaluating potential genetic modifiers of cancer risk in BRCA1 and BRCA2 carriers ( Over 20,000 carriers from 35 centres have been enrolled, about 50% of whom are affected with breast cancer and 10% with ovarian cancer.

Additional information